We are live on
!
Find out more
Arbutus Biopharma
ABUS
ABUS
122 hedge funds and large institutions have $189M invested in Arbutus Biopharma in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
327% more call options, than puts
Call options by funds: $5.24M | Put options by funds: $1.23M
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
50% more capital invested
Capital invested by funds: $126M → $189M (+$62.9M)
16% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 32
7% more funds holding
Funds holding: 114 → 122 (+8)
3.79% more ownership
Funds ownership: 34.65% → 38.44% (+3.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
122
Holders Change
+8
Holders Change %
+7.02%
% of All Funds
1.94%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
20
Increased
37
Reduced
32
Closed
11
Calls
$5.24M
Puts
$1.23M
Net Calls
+$4.01M
Net Calls Change
+$2.04M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$13.1M |
| 2 |
WCM
Whitefort Capital Management
New York
|
+$10.3M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$7.5M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.06M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.11M |
Top Sellers
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$5.97M |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$2.54M |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$1.66M |
| 4 |
BlackRock
New York
|
-$667K |
| 5 |
Millennium Management
New York
|
-$542K |
